Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DENTSPLY SIRONA Inc.'s SEC filings document regulatory disclosures for a diversified dental products and technology manufacturer listed on Nasdaq under XRAY. Recent Form 8-K reports furnish operating results, GAAP and non-GAAP reconciliations, outlook commentary, distribution agreements, product and regulatory updates, restructuring actions and capital allocation changes involving dividend policy, debt reduction and share repurchases.
The company's proxy and governance filings cover director elections, board composition, committee assignments, executive compensation and stockholder meeting matters. Other current reports disclose board expansion, director appointments, chief financial officer transition matters, separation arrangements and Regulation FD communications tied to commercial agreements and corporate updates.
DENTSPLY SIRONA Inc. reported the results of its annual meeting of stockholders held on June 2, 2026. Stockholders elected twelve directors to serve until the next annual meeting or until successors are elected and qualified, with each nominee receiving more votes "For" than "Against."
Stockholders ratified the appointment of Deloitte & Touche LLP as independent registered public accountants for 2026, with 182,033,381 votes in favor. They also approved, on a non-binding advisory basis, the Company’s 2025 executive compensation. In addition, stockholders approved an amendment to the 2024 Omnibus Incentive Plan to increase the number of shares of common stock issuable under the plan by 15,000,000 shares.
DENTSPLY SIRONA Inc. President and CEO Daniel T. Scavilla reported a routine tax-related share disposition. On May 22, 2026, 4,095 shares of common stock were withheld at $10.21 per share to cover taxes tied to vesting of his Restricted Stock Units and related dividend equivalent units.
After this withholding, Scavilla directly holds 157,754 shares of DENTSPLY SIRONA common stock. The transaction reflects tax withholding, not an open-market sale or discretionary trade.
Dentsply Sirona reported Q1 2026 results showing flat sales but weaker profitability while reiterating its full-year outlook. Net sales were $880 million versus $879 million a year ago, but GAAP results swung to a net loss of $10 million, or ($0.05) per share, from earnings of $20 million, or $0.10 per share.
On a non-GAAP basis, adjusted EPS was $0.27, down from $0.44, and adjusted EBITDA fell to $129 million with margin declining to 14.7% from 19.0%. Constant currency sales decreased 6.7% as growth in Wellspect Healthcare offset softer trends in Orthodontic and Implant Solutions and Essential Dental Solutions.
Operating cash flow improved to $40 million from $7 million, while free cash flow remained at negative $12 million. Cash and cash equivalents were $190 million and total equity was $1.3 billion as of March 31, 2026. The company highlighted the launch of its AI-enabled Smart View‑Detect diagnostic aid, new distribution agreements, and ongoing restructuring and capital allocation efforts, and maintained 2026 guidance for net sales of $3.5–$3.6 billion and adjusted EPS of $1.40–$1.50.
DENTSPLY SIRONA Inc (Common Stock, CUSIP 24906P109) is reported in a Schedule 13G by Vanguard Capital Management. The filing states Vanguard beneficially owns 10,529,427 shares, representing 5.27% of the class. The filer reports 1,529,870 shares of sole voting power and 10,529,427 shares of sole dispositive power. The filing lists Vanguard's Malvern, PA address and is signed by Ashley Grim, Head of Global Fund Administration, dated 04/29/2026.
Vanguard Portfolio Management reports beneficial ownership of 10,724,505 shares of DENTSPLY SIRONA Inc. (Common Stock, CUSIP 24906P109), representing 5.36% of the class as of 03/31/2026. The filing shows sole voting power for 193,759 shares and sole dispositive power for 10,724,505 shares. The Schedule 13G was signed on 04/29/2026 by Ashley Grim, Head of Global Fund Administration, and discloses holdings held or managed across Vanguard affiliates and client accounts.
DENTSPLY SIRONA Inc. is calling a virtual 2026 Annual Meeting of Stockholders on June 2, 2026 at 8:00 a.m. Eastern Time. Stockholders of record on April 6, 2026, representing 200,320,502 common shares, can vote online, by phone, by mail, or during the webcast.
They will vote on electing twelve directors, ratifying Deloitte & Touche LLP as independent auditors for 2026, approving 2025 executive compensation on a non-binding basis, and amending the 2024 Omnibus Incentive Plan to increase the common stock issuable under the plan by 15,000,000 shares.
MAZELSKY JONATHAN JAY reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky received a grant of phantom stock under the Directors' Deferred Compensation program. The award covers 2,644.6402 phantom stock units at an economic reference price of $11.34 per unit, each tied to one share of common stock.
Following this compensation grant, his balance in this phantom stock account increased to 17,179.8540 units. According to the terms, these phantom stock units are economically equivalent to common shares and will be settled in common stock after his termination of service as a director.
DENTSPLY SIRONA Inc ownership update: The Vanguard Group filed an Amendment No. 18 to a Schedule 13G/A reporting 0 shares beneficially owned and 0% of the class. The filing explains an internal realignment at The Vanguard Group that disaggregated certain subsidiaries for separate reporting in reliance on SEC Release No. 34-39538.
The filing is signed by Ashley Grim, Head of Global Fund Administration, and lists Vanguard's registered address in Malvern, Pennsylvania.